Prevalence of Bloodstream Pathogens Is Higher in Neonatal Encephalopathy Cases vs. Controls Using a Novel Panel of Real-Time PCR Assays

Cally J. Tann1,5*, Peter Nkurunziza2, Margaret Nakakeeto3, James Oweka2, Jennifer J. Kurinczuk6, Jackson Were2, Natasha Nyombi5, Peter Hughes3, Barbara A. Willey1, Alison M. Elliott1,2, Nicola J. Robertson1,7, Nigel Klein4,7, Kathryn A. Harris4,7

1 Clinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, 2 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda, 3 Institute for Women’s Health, University College London, Medical School Building, London, United Kingdom, 4 Institute for Child Health, University College London, London, United Kingdom, 5 Mulago University Hospital, Kampala, Uganda, 6 National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, 7 Department of Microbiology, Virology and Infection Control, Great Ormond Street Hospital for Children, London, United Kingdom

Abstract

Background: In neonatal encephalopathy (NE), infectious co-morbidity is difficult to diagnose accurately, but may increase the vulnerability of the developing brain to hypoxia-ischemia. We developed a novel panel of species-specific real-time PCR assays to identify bloodstream pathogens amongst newborns with and without NE in Uganda.

Methodology: Multiplex real-time PCR assays for important neonatal bloodstream pathogens (gram positive and gram negative bacteria, cytomegalovirus (CMV), herpes simplex virus(HSV) and P. falciparum) were performed on whole blood taken from 202 encephalopathic and 101 control infants. Automated blood culture (BACTEC) was performed for all cases and unwell controls.

Principal Findings: Prevalence of pathogenic bacterial species amongst infants with NE was 3.6%, 6.9% and 8.9%, with culture, PCR and both tests in combination, respectively. More encephalopathic infants than controls had pathogenic bacterial species detected (8.9%vs2.0%, p = 0.028) using culture and PCR in combination. PCR detected bacteremia in 11 culture negative encephalopathic infants (3 Group B Streptococcus, 1 Group A Streptococcus, 1 Staphylococcus aureus and 6 Enterobacteriaceae), Coagulase negative staphylococcus, frequently detected by PCR amongst case and control infants, was considered a contaminant. Prevalence of CMV, HSV and malaria amongst cases was low (1.5%, 0.5% and 0.5%, respectively).

Conclusion/Significance: This real-time PCR panel detected more bacteremia than culture alone and provides a novel tool for detection of neonatal bloodstream pathogens that may be applied across a range of clinical situations and settings. Significantly more encephalopathic infants than controls had pathogenic bacterial species detected suggesting that infection may be an important risk factor for NE in this setting.

Citation: Tann CJ, Nkurunziza P, Nakakeeto M, Oweka J, Kurinczuk JJ, et al. (2014) Prevalence of Bloodstream Pathogens Is Higher in Neonatal Encephalopathy Cases vs. Controls Using a Novel Panel of Real-Time PCR Assays. PLoS ONE 9(5): e97259. doi:10.1371/journal.pone.0097259

Editor: Sudha Chaturvedi, Wadsworth Center, United States of America

Received February 14, 2014; Accepted April 14, 2014; Published May 16, 2014

Copyright: © 2014 Tann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Wellcome Trust through the London School of Hygiene & Tropical Medicine Clinical PhD programme [grant 094016/Z/10/Z to CT]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: cally.tann@lshtm.ac.uk

Introduction

Identification of bloodstream infections in newborns, either alone or as a co-morbidity amongst infants affected by conditions such as neonatal encephalopathy (NE), is problematic. Clinical signs associated with neonatal sepsis syndrome, such as lethargy, poor feeding and convulsions, overlap substantially with other conditions such as NE. In preclinical studies exposure to bacterial endotoxin has been shown to increase vulnerability of the developing brain to perinatal hypoxia-ischemia [1–3]. However, clinical studies have yet to precisely define the relationship between perinatal infections and neonatal encephalopathy (NE).

Fetal exposure to inflammation and, or, infection has also been found to increase brain vulnerability to hypoxia-ischemia via stimulation of toll-like receptors, immune and inflammatory responses, chemotaxis and cell death[4–6]. If implicated, the high prevalence of perinatal infections in the African setting means the contribution to the etiology of NE may be substantial.

The use of pediatric blood culture techniques in the neonatal period is complicated by low circulating bacterial load, the small volumes of blood taken, and because intrapartum antibiotics may render bacteria non-viable. Open techniques for taking neonatal blood samples increase the risk of contamination with commensal organisms making interpretation of results problematic. In
Table 1. Primer and probe target genes, sensitivities and sequences for the Real-Time PCR assays.

| Organism                  | Target gene | Assay sensitivity | Reference | Primer and probe sequences | Multiplex Reaction Mixtures |
|---------------------------|-------------|-------------------|-----------|----------------------------|-----------------------------|
| *Staphylococcus aureus*   | coa         | 0.1–1 cfu/reaction| Sabet 2006| coa-forward: 5′-GTAGATGGGCAATCATTTTGAGG |
|                           |             |                   |           | coa-reverse: 5′-CGGATCTGCTCTTGATCCCATGTA |
|                           |             |                   |           | coa-probe: 5′-FAM- TAGGCGACATTGAGTTGAC-BHQ1 |
| *Streptococcus pyogenes*  | csrR        | 0.1–1 cfu/reaction| This study| GAS-forward: 5′-TGATGTTGCTGGACAGTTGAC |
|                           |             |                   |           | GAS-reverse: 5′-CGGGAATGTCTCTATCTGAG |
|                           |             |                   |           | GAS-probe: 5′-JOE- CGGTGCAGAATGCTCTGAG |
| *Streptococcus pneumoniae*| lytA        | 0.1–1 cfu/reaction| Harris et al 2008 | lytA-forward: 5′-ACGCAATCTAGCAGATGAAGC |
|                           |             |                   |           | lytA-reverse: 5′-TGTTTGGTTGGTTATTCGTGC |
|                           |             |                   |           | lytA-probe: 5′-FAM- TTTGCCGAAACGGCTTCTACAGGG-BHQ1 |
| *Streptococcus agalactiae*| sip         | 0.1–1 cfu/reaction| Berseng et al 2007/Probe this study | GBS-forward: 5′-ATCCCTGAGACACACTGAAG |
|                           |             |                   |           | GBS-reverse: 5′-TTGCTGGTTCTTTATTTCA |
|                           |             |                   |           | GBS-probe: 5′-JOE- ATCGAGAGCTACCTACATC-GYACTC-BHQ1 |
| *Enterobacteriaceae*      | dnaK        | 1–10 cfu/reaction | This study| ent-forward: 5′-ACCTGGGTACWACCAACTCTTGTT |
|                           |             |                   |           | ent-reverse: 5′-GTCACTGCTAGCTGATGC |
|                           |             |                   |           | ent-probe: 5′-JOE-AGGAGTGGAAACACTCCTGAGG |
| *Staphylococcus species*  | tuf         | 1–10 cfu/reaction | This study| tuf-forward: 5′-CATTCAATCCGAGACTGGAAT |
|                           |             |                   |           | tuf-reverse: 5′-CAGGACCAGTGATGGAATACG |
|                           |             |                   |           | tuf-probe: 5′-CY5-TGAAYAAACATTGATGAGCAGT |

*Mix 1*: 1X QuantiFast Multiplex PCR mastermix (Qiagen), 0.15 μM each of coa-forward, coa-reverse and coa-probe, 0.3 μM each of GAS-forward and GAS-reverse, 0.2 μM GAS-probe, 0.1 μM each of IPC-forward, IPC-reverse, IPC-probe, 7 μl extracted DNA and molecular grade water to give a final reaction volume of 20 μl.

*Mix 2*: 1X QuantiFast Multiplex PCR mastermix (Qiagen), 0.2 μM each of lytA-forward, lytA-reverse, lytA-probe, GBS-forward, GBS-reverse and GBS-probe, 7 μl extracted DNA and molecular grade water to give a final reaction volume of 20 μl.

*Mix 3*: 1X QuantiFast Multiplex PCR mastermix (Qiagen), 0.25 μM each of ent-forward, ent-reverse and ent-probe, 0.1 μM each of tuf-forward, tuf-reverse and tuf-probe, 7 μl extracted DNA and molecular grade water to give a final reaction volume of 20 μl.
| Organism             | Target gene | Assay sensitivity | Reference     | Primer and probe sequences                          | Multiplex Reaction Mixtures                                                                 |
|---------------------|-------------|-------------------|---------------|-----------------------------------------------------|---------------------------------------------------------------------------------------------|
| CMV                 | DNA polymerase | 5 copies/reaction  | This study    | CMV-forward: 5'-GCATGCGCGAGTGCAAGAC                 | Mix 4: 1X QuantiFast Multiplex PCR mastermix (Qiagen), 0.2 μM each of CMV-forward, CMV-reverse, CMV-probe, P. fal-forward, P. fal-reverse and P. fal-probe, 7 μl extracted DNA and molecular grade water to give a final reaction volume of 20 μl |
|                     |             |                   |               | CMV-reverse: 5'-GTACTTTGAGCGCCATCTGTTCCT            |                                                                                               |
|                     |             |                   |               | CMV-probe: 5'-CY5-TGCAGCGCTGATGCTGACCA-BBB          |                                                                                               |
| Plasmodium falciparum| SSU RNA     | <3 parasites/ul   | Adegnika et al. 2006 | Plas-forward: 5'-CCG ACT AGG TTG TGG ATG AAA GTG TTA A  | Mix 5: 1X QuantiFast Multiplex PCR mastermix (Qiagen), 0.4 μM each of HSV-forward and HSV-reverse, 0.2 μM each of HSV-1-probe and HSV-2-probe, 7 μl extracted DNA and molecular grade water to give a final reaction volume of 20 μl |
|                     |             |                   |               | Plas-reverse: 3'-AAC CCA AAG ACT TTG ATT TCT CAT AA  |                                                                                               |
|                     |             |                   |               | Pfal-probe: 5'-FAM-CTT TCG AGG TGA CTT TTA GAT-      |                                                                                               |
| HSV 1 and 2         | DNA polymerase | 5 copies/reaction  | This study    | HSV-forward: 5'-GACAAGCAATTCCAGATGCTG               |                                                                                               |
|                     |             |                   |               | HSV-reverse: 5'-ATGTTTGACCCGGTCCAGA-Act             |                                                                                               |
|                     |             |                   |               | HSV1-probe: 5'-FAM-CATGACCCCTTGTGAAAACA-MGB         |                                                                                               |
|                     |             |                   |               | HSV-2-probe: 5'-VIC-TGACCTTCGTCAAGCAG-MGB           |                                                                                               |
contrast, real-time PCR techniques need less blood (<500 ul) and can detect the presence of non-viable bacteria. Additionally, real-time PCR assays are semi-quantitative, facilitating differentiation of clinically significant results from contamination.

Despite being a potentially useful adjunct to culture, real-time PCR for the diagnosis of typical sepsis pathogens from blood in any group is not frequently reported in the literature. The majority of studies using molecular techniques to diagnose bloodstream infections in neonates have focused on broad-range bacterial PCR assays, mainly those targeting 16 S rDNA [7]. However, despite the ability of such assays to detect a wide range of bacterial species their sensitivity is limited by ubiquitous contamination of PCR reagents with bacterial DNA [8,9]. Well-designed and optimized species-specific real-time PCR assays offer 100-fold greater sensitivity [10].

Our aim was to develop a novel panel of species-specific real-time PCR assays to identify bloodstream pathogens in term infants with NE in Uganda and to compare the prevalence of pathogenic bacterial species between encephalopathic infants and unaffected controls.

Methods

Ethics Statement

London School of Hygiene & Tropical Medicine, Uganda Virus Research Institute (UVRI) and the Uganda National Council on Science and Technology ethics committees approved the study. Informed written parental consent was taken for all study participants.

Infants were recruited to a larger epidemiological study examining perinatal risk factors for NE in Uganda (the ‘ABANNA study’) September 2011 through October 2012. Infants were recruited at Mulago Hospital, Kampala, Uganda’s National Referral Hospital. Participants were in-born term infants, <12 hours of age. Cases were infants with NE defined according to the Thompson clinical scoring system [11] with case infants scoring ≥6 and controls ≤3. Concurrently recruited unmatched controls were randomly selected from labor ward admissions. Exclusion criteria included living >20 km radius of Mulago Hospital, neonatal intravenous antibiotics administered prior to recruitment and parental consent declined.

Aseptic non-touch venepuncture was performed by trained clinical study staff: 0.5 ml blood (EDTA microfuge tube) for...

Table 2. Baseline demographic and clinical characteristics of mothers and babies.

| Characteristic                  | Case            | Control         | P-value*      |
|---------------------------------|-----------------|-----------------|---------------|
|                                 | N(%)            | N(%)            |               |
| Maternal                        |                 |                 |               |
| Maternal education=primary level| 79/202 (39.1)   | 45/100 (45.0)   | 0.327         |
| Nulliparity                     | 118/202 (58.4)  | 49/101 (48.5)   | 0.102         |
| Emergency caesarean section     | 49/201(24.4)    | 23/101(22.8)    | 0.757         |
| Intrapartum antibiotics         | 37/201 (18.4)   | 16/101 (15.8)   | 0.580         |
| Neonatal                        |                 |                 |               |
| Male sex                        | 132/202 (65.4)  | 48/101 (47.5)   | 0.003         |
| Mean birth weight (g)           | 3183            | 3033            | 0.0061        |
| 1 minute APGAR <3               | 65/195 (33.3)   | 1/99 (1)        | <0.0001       |
| 5 minute APGAR <7               | 126/177 (71.2)  | 1/98 (1)        | <0.0001       |
| Case fatality                   | 68/200(34.0)    | 0/96 (0.0)      | <0.0001       |

*chi-squared test.

doi:10.1371/journal.pone.0097259.t002
Table 3. Comparison of species specific bacterial qPCR and BACTEC blood culture for detection of pathogenic bacteria in blood samples amongst neonatal encephalopathy case infants.

| Blood Culture | Positive | Negative |
|---------------|----------|----------|
| PCR Positive  | 3        | 11       |
| PCR Negative  | 4        | 184      |

Table 4. Results of blood culture, real-time PCR assays and sequencing of positives.

| Patient  | Blood culture | PCR  | Sequence | Intrapartum antibiotics | CRP Day 1 | CRP Day 3 |
|----------|---------------|------|----------|--------------------------|-----------|-----------|
| GROUP B STREPTOCOCCUS | | | | | | |
| Case 61  | Coagulate Negative Staphylococcus | Group B Streptococcus | – | Yes | 16.86 | 50.4 |
| Case 81  | Negative | Group B Streptococcus | – | No | 47.52 | Died D1 |
| Case 170 | Negative | Group B Streptococcus | – | No | 4.23 | Died D1 |
| OTHER STREPTOCOCCUS | | | | | | |
| Case 133 | Negative | Group A Streptococcus | – | No | 61.16 | Died D1 |
| Case 150 | Group C Streptococcus | Negative | – | No | 0.28 | 1.02 |
| STAPHYLOCOCCUS AUREUS | | | | | | |
| Case 37  | S. aureus | Negative | – | No | 6.22 | 4.03 |
| Case 83  | Negative | S. aureus | – | No | 2.28 | 30.4 |
| Case 157 | S. aureus | Negative | – | Yes | 81.55 | 63.06 |
| Case 166 | S. aureus | Negative | – | No | 8.18 | 20.41 |
| Control 5 | Not performed | S. aureus | – | No | 55.56 | n/a |
| GRAM NEGATIVE ORGANISMS | | | | | | |
| Case 41  | Negative | Enterobacteriaceae | Enterobacter sp. | No | 7.58 | insuff |
| Case 53  | E.Coli | Enterobacteriaceae | E.coli or Klebsiella sp. | No | 1.1 | Died D1 |
| Case 56  | Negative | Enterobacteriaceae | Failed | No | 0.47 | Died D1 |
| Case 64  | Negative | Enterobacteriaceae | Failed | No | 0.22 | 13.16 |
| Case 67  | Negative | Enterobacteriaceae | Enterobacter sp. | No | 0.14 | Died D1 |
| Case 82  | Negative | Enterobacteriaceae | Pantoea sp. | No | 8.91 | Died D1 |
| Case 117 | Negative | Enterobacteriaceae | E.Coli | Yes | 32.81 | Died D1 |
| MULTIPLE ORGANISMS | | | | | | |
| Case 132 | S. aureus | Enterobacteriaceae | E.Coli | – | No | 49.01 | – |
| Case 49  | Klebsiella sp. | Enterobacteriaceae | Klebsiella sp. | Yes | 3.61 | 9.32 |
| Control 65 | Not performed | Enterobacteriaceae | E.Coli | No | 1.83 | n/a |
| VIRUSES & MALARIA | | | | | | |
| Case 10  | Negative | Cytomegalovirus | – | n/a | 2.68 | Died D1 |
| Case 16  | Negative | Cytomegalovirus | – | n/a | 0.16 | Died D1 |
| Control 21 | Not perform | Cytomegalovirus | – | n/a | 0.32 | n/a |
| Case 175 | Negative | Herpes Simplex Virus 1 | – | n/a | 0.35 | 2.79 |
| Control 98 | Not performed | P. falciparum | – | n/a | 1.38 | n/a |

doi:10.1371/journal.pone.0097259.t003
doi:10.1371/journal.pone.0097259.t004
quantitative PCR (all infants), 0.5–1.0 ml whole blood inoculated into a single pediatric blood culture (BC) bottle (BACTEC Peds Plus, Becton Dickinson, Sparks MD; all cases and control infants clinically unwell on assessment), and 0.5 ml (serum microfuge tube) for C-reactive protein (CRP) (all infants, COBAS, Roche Diagnostics). A repeat sample for CRP was taken after 48 hours amongst surviving cases. Culture bottles were loaded into the Bactec 9240 automated instrument at the MRC/UVRI microbiology laboratory. Gram-stained, subcultured, and purified colonies were manually identified from positive cultures.

Bead-beating of EDTA-blood samples (300 μl) was performed to ensure complete lysis of bacterial cells. DNA (200 μl elute) was extracted using the QiAmp DNA blood mini kit and a QIAcube semi-automated extraction platform (both Qiagen, Manchester, UK). Each batch (12 samples) included a negative extraction control (200 μl of buffer AE, Qiagen). CT and PN performed all DNA extraction in the MRC/UVRI virology laboratories.

Ten targets and an internal control were amplified in five separate multiplexed reactions (Table 1) on a 7500 Fast Real Time PCR system (Life Technologies, Paisley, UK). Cycling conditions were 95°C for 5 minutes then 45 cycles of 95°C for 30 seconds and 60°C for 30 seconds. A positive result was any target detected with a cycle-threshold (CT) value <38. A no template control was included for each multiplexed assay. A positive control was included for every target organism. For bacterial targets this was DNA extracted from suspensions of cultured laboratory strains of known provenance, for viral targets this was plasmid DNA and for Plasmodium falciparum this was a microscopically positive clinical sample. A valid run required detection of each positive control with a CT value within a set range (normally 28.5–31.5). For bacterial assays suspensions of control organisms were quantified using a plate-counting method and for viral assays plasmid DNA was quantified using the NanoDrop Spectrophotometer (Labtech, Uckfield, UK). PCR assays were performed in the laboratories of UVRI and Great Ormond Street Hospital (GOSH), by CT and KH. Clinical staff and technicians were not blinded to case control status. Blood culture results were not available to staff prior to performing PCR assays.

Enterobacteriaceae PCR positives were further identified by amplicon sequencing using Big-Dye 3.1 Cycle-sequencing kit (Life Technologies) and analyzed on a 3130 Genetic Analyse (Life Technologies). Sequences were compared to an in-house database of Enterobacteriaceae dnaK sequences using MegAlign (Lasergene 10, DNASTar, Madison, WI, USA) or by BLAST searching against the Genbank database (http://www.ncbi.nlm.nih.gov).

The prevalence of bacteremia between cases and controls was compared using the Chi-squared test using STATATA version 12.0.

Results

Samples from 202 case and 101 controls were examined (Figure 1). Most encephalopathic infants were moderately or severely affected (89.1%, n = 180). Compared to controls they were more likely to be male, have abnormal APGAR scores at one and five minutes, and have a higher mean birth weight (Table 2). Intrapartum antibiotic use was similar.

Comparison of Bacterial PCR and Culture Results amongst Infants with NE vs. Controls

The prevalence of neonatal bacteremia with a pathogenic organism amongst encephalopathic infants was 3.5% (7) by BC alone, 6.9% (14) by PCR alone and 8.9% (18) by BC and PCR in combination (Table 3). Of the 101 control infants, none was positive for pathogenic bacterial species on BC but two were positive on PCR, giving a prevalence of neonatal bacteremia amongst the control group of 2.0% (2/101). Four control infants were clinically unwell on recruitment, so BCs were performed in addition to PCR; all 4 were negative on both tests. The prevalence of bacteremia (by either BC or PCR) was significantly higher amongst infants with encephalopathy than those without (9.9% vs. 2.0% respectively, p-value = 0.020). Coagulase negative staphylococcus (CoNS), usually considered non-pathogenic amongst term newborns, was more commonly found on PCR amongst controls compared to cases, but this difference was not statistically significant (9.9% (9/101) in controls vs. 5.5% (11/202) in cases, p = 0.252).

Case Infants with Positive Blood-cultures

Seven case infants had a positive BC; four of these (3 Staphylococcus aureus and 1 Group C Streptococcus) were PCR negative. The other three cases also yielded a positive PCR result; one E. coli by both methods, a second S. aureus by both methods but also PCR positive for the Enterobacteriaceae target and a third case was BC positive for CoNS but PCR positive for Group B Streptococcus (GBS) (Table 4).

Cases with Negative Blood-cultures

One hundred and ninety five case infants had negative BCs, 184 of these were also negative by PCR. The remaining 11 BC negative cases were positive by real-time PCR for a bacterial target (3 GBS, 1 Group A Streptococcus (GAS), 1 S. aureus and 6 Enterobacteriaceae). Of the five infants PCR positive, BC negative for pathogenic streptococcal or staphylococcal species, four had substantially raised CRP levels on day 1 or day 3 and the fifth (case 170) died <24 hours after a course consistent with aggressive GBS septicemia with persistent hyperthermia, severe respiratory distress and seizures. Sequencing of the Enterobacteriaceae amplicon in the 6 positive cases allowed identification of a pathogenic organism (at least to genus level) in 4 cases (2 Enterobacter sp., 1 Pantoea sp. and 1 E. coli) but was unsuccessful in 2 cases these are identified only as Enterobacteriaceae (Table 4). In the absence of normative CRP data for this population, a raised CRP was defined as CRP>97th centile amongst controls (≥40.7 mg/L). Of case infants without evidence of bacteremia on PCR or BC, 5.0% (9/181) had a raised CRP on day one, rising to 16.2% (19/117) on day 3 amongst survivors. Bacteraemic case infants were significantly more likely to have a raised CRP on day one compared to non-bacteraemic infants (22.2% (4/18) vs. 5.0% (9/181), p = 0.005).

Cytomegalovirus, Herpes Simplex & Malaria

The prevalence of cytomegalovirus (CMV) infection was 1.5% (3/202) amongst cases and 1.0% (1/101) in controls. Herpes simplex virus (HSV) was identified in one case infant (0.5%) and P. falciparum in one case and one control infant.

Discussion

The accurate diagnosis of infectious co-morbidity in the unwell newborn through clinical signs or standard culture techniques is problematic [12]. Our novel panel of multiplexed real-time PCR assays, designed to cover the majority of common pathogens implicated in congenital neonatal infections, was successful in detecting more bacteremia than culture alone amongst encephalopathic Ugandan newborns. A significantly higher prevalence of potentially pathogenic bacterial species was seen in encephalopathic babies when compared to controls suggesting that fetal
exposure to bacterial blood-borne pathogens may be a causal factor for neonatal encephalopathy in this setting. This may be mediated by cytokines and inflammatory cells which have been found to be intermediaries in perinatal brain injury secondary to hypoxia-ischemia, neurotoxins and infection [13] or by enhanced sensitivity of the brain to hypoxia-ischemia after exposure to bacterial products such as endotoxin.

Eleven culture-negative encephalopathic infants tested positive on bacterial PCR for pathogenic organisms. Amongst these, two organisms could only be identified and as Enterobacteriaceae and as this family contains environmental non-pathogenic species, interpretation of these two PCR positives is uncertain. Coagulase negative staphylococcus, considered non-pathogenic in the absence of indwelling catheters, was common amongst both case and control infants. Open venepuncture may have contributed to an increased contamination risk. False positive PCR results due to laboratory contamination are unlikely since negative controls were consistently negative and strict laboratory practice was followed to prevent contamination.

The prevalence of congenital cytomegalovirus (CMV) is thought to be high in low income settings (1–5%) where it is commonly secondary to non-primary maternal infections [14]. No Ugandan studies have published rates of congenital CMV infection. Our prevalence of 1.1% amongst controls is substantially lower than that reported from a recent birth cohort in the Gambia (5.4%) [15]. Our prevalence of congenital CMV was similar between encephalopathic and non-encephalopathic infants suggesting that CMV does not contribute to the burden of neonatal encephalopathy in this setting. Herpes Simplex and P. falciparum infections were similarly uncommon.

There are limitations of all laboratory techniques utilized in the detection of bacteremia. In our study, important pathogens such as GBS, S. aureus and Enterobacteriaceae were detected by PCR but not culture; however bacteremia in four infants was detected by culture alone. This was most common for S. aureus, a robust organism that grows well in the laboratory hence culture may be more sensitive than PCR for detecting low levels of S. aureus bacteremia in these infants. Even a combination of PCR and culture is unlikely to exclude all infants with early sepsis, highlighted by the substantial number of culture negative/PCR negative infants with a substantially raised CRP on either day one or day 3. This emphasizes the importance of empirical antibiotic therapy to all sick newborns including those with NE. In addition, PCR assays offer no information on antimicrobial susceptibility, and contamination with commensal and environmental organisms remains an issue for all techniques.

In conclusion, we have found high levels of bacteremia in infants with NE in an African setting using a combination of blood culture and species-specific real-time PCR assays to identify bloodstream pathogens. Significantly more encephalopathic infants than controls had pathogenic bacterial species detected suggesting that neonatal bacteremia may be an important risk factor for NE in this setting. Our real-time PCR panel detected more bacteremia than culture alone and provides a novel tool for detection of neonatal bloodstream pathogens that could be applied across a range of clinical situations and settings.

Acknowledgments

We would like to acknowledge the contribution of the maternity and neonatal staff at Mulago Hospital for their assistance in recruiting of study infants, the National Influenza Centre at the Uganda Virus Research Institute and the Virology department at the MRC/UVRI Ugandan Research Unit on AIDS who provided essential laboratory facilities to perform the PCR assays. Thanks also to the families who participated in the ABAaNA study.

Author Contributions

Conceived and designed the experiments: CJT KAH NK NJR AME JJK. Performed the experiments: CJT PN KAH JO JW. Analyzed the data: CJT KAH BAW NK. Contributed reagents/materials/analysis tools: KAH NK CJT AME PH. Wrote the paper: CJT KAH NJR NK AME JJK BAW. Participant recruitment and data collection: NN MN.

References

1. Eklind S, Mallard C, Leverin AL, Gilland E, Biomgren K, et al. (2001) Bacterial endotoxin sensitizes the immature brain to hypoxic-ischaemic injury. Eur J Neurosci 13: 1101–1106.
2. Mallard C, Welin AK, Peebles D, Hagberg H, Kjellner I (2003) White matter injury following systemic endotoxemia or asphyxia in the fetal sheep. Neurochem Res 28: 215–223.
3. Eklind S, Mallard C, Arvidsson P, Hagberg H (2005) Lipopolysaccharide induces both a primary and a secondary phase of sensitization in the developing rat brain. Pediatric Research 58: 112–116.
4. Mallard C (2012) Innate immune regulation by Toll-like receptors in the brain. ISRN Neurology 2012: 19.
5. Stridh L, Motta Hedén A, Johansson ME, Valdez RC, Northington F, et al. (2013) Toll-like receptor-3 increases the vulnerability of the neonatal brain to hypoxia-ischaemia. Journal of Neurosurgery 33: 12041–12051.
6. Peebles D (2007) Intrarretinal infection and perinatal brain injury. 1–7 p.
7. Pannu M, Hors A, Leelang M, Versalovic J (2011) Molecular assays in the diagnosis of neonatal sepsis: A systematic review and meta-analysis. Pediatrics 128: e975–e985.
8. Harris KA, Hartley JC (2003) Development of broad-range 16 rDNA PCR for use in the routine diagnostic clinical microbiology service Journal of Medical Microbiology 5: 685–691.
9. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Kazmansk EB, et al. (2000) Contamination and sensitivity issues with a real-time universal 16S rRNA PCR. Journal of Clinical Microbiology 38: 1747–1752.
10. Harris KA, Turner P, Green EA, Hartley JG (2008) A duplex real-time PCR assay for the detection, and determination of penicillin susceptibility, of Streptococcus pneumoniae in clinical samples Journal of Clinical Microbiology 46: 2751–2758.
11. Thompson CM, Puterman AS, Linley LA, Hahn FM, van der Elst CW, et al. (1997) The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr 86: 757–761.
12. Edmond K, Zaidi A (2010) New approaches to preventing, diagnosing, and treating neonatal sepsis. Plos Medicine 7: e1000213.
13. McAdams R, Juul S (2012) The role of cytokines and inflammatory cells in perinatal brain injury. Neurology Research International 13 pages.
14. Manicklal S, Emery VG, Lazzarotto T, Boppana SB, Gupta RK (2013) The “Silent” Global Burden of Congenital Cytomegalovirus. Clinical Microbiology Reviews 26: 86–102.
15. van der Sande MAB, Kaye S, Miles HJC, Waight P, Jeffries DJ, et al. (2007) Risk factors for and Clinical Outcome of Congenital Cytomegalovirus Infection in a Peri-Urban West-African Birth Cohort. Plos ONE 2: e492.